--- canonical_name: sh-Polypeptide-71 alternate_names: Vasoactive Intestinal Peptide, VIP, sh-Polypeptide-65, Synthetic Human Vasoactive Intestinal Peptide canonical_topic: sh-Polypeptide-71 for Hair Regrowth short_topic_lc: sh_polypeptide_71_hair creation_date: 2026-0708-2106 creator_ai_fullname: Opus 4.8 ep_keywords: Neuropeptides, Growth Factor Peptides, Cosmetic Peptides --- # sh-Polypeptide-71 for Hair Regrowth
Evidence Review created on 07/08/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8 **Also known as:** Vasoactive Intestinal Peptide, VIP, sh-Polypeptide-65, Synthetic Human Vasoactive Intestinal Peptide ## Motivation sh-Polypeptide-71 is a laboratory-made copy of a natural body signal called vasoactive intestinal peptide (VIP). The "sh-" label marks it as a synthetic human version — a short chain of amino acids identical to one the body already makes. Inside the body this signal widens blood vessels and calms inflammation. Cosmetic makers now add it to leave-on scalp serums, usually blended with other synthetic growth signals, hoping to wake resting hair follicles and encourage thicker regrowth. The molecule was first identified in the gut in the early 1970s and has mostly been studied for its effects on blood flow and immunity. Its move into hair care is recent and rides a broader wave of "growth-factor" and peptide serums sold for thinning hair. The interest rests on a simple idea: if a signal improves blood supply and quiets inflammation elsewhere, perhaps it can do the same around a struggling follicle. This review examines what is known about sh-Polypeptide-71 for hair regrowth: how it is proposed to work, what the laboratory and human evidence does and does not show, its likely benefits and risks, and the practical questions around the serums containing it. Throughout, it separates marketing claims from tested findings. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overview material that discusses the mechanism and therapeutic category most relevant to sh-Polypeptide-71 — the role of nerve signals such as VIP in the hair follicle. * [Neuroendocrinology of the hair follicle: principles and clinical perspectives](https://pubmed.ncbi.nlm.nih.gov/25066729/) - Paus et al., 2014 A narrative review of how nerve- and hormone-derived signals, including neuropeptides such as VIP, govern the hair growth cycle. It is the best single high-level overview of the biological category that sh-Polypeptide-71 is marketed to act on. * [Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides](https://pubmed.ncbi.nlm.nih.gov/11179999/) - Peters et al., 2001 A primary laboratory study showing that nerve-derived peptides actively push the follicle into or out of its growth phase, with the VIP-family marker mapped across the hair cycle. It illustrates why neuropeptides are plausible — but unpredictable — modulators of hair growth. * [Sequential expression of glutathione-S-transferase isoenzymes during hair growth phases in mice and their relationship to caldesmon, phosphotyrosinase and VIP receptor protein](https://pubmed.ncbi.nlm.nih.gov/7756742/) - Wollina et al., 1995 The most VIP-specific hair study available: it maps the VIP receptor to the follicle bulge during the growth phase and proposes that VIP signaling may help end, rather than extend, active growth — an important caution for anyone assuming VIP promotes regrowth. **Note:** Only three eligible high-quality sources could be found, and all are academic rather than consumer-facing, because sh-Polypeptide-71 is an obscure cosmetic ingredient with no dedicated expert commentary. The list was not padded with product-seller blog posts. No relevant content was found from the priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension): searches of their platforms returned general hair-loss and peptide material (e.g., Peter Attia's hair-loss Q&A and Andrew Huberman's hair episode) but nothing addressing sh-Polypeptide-71 or VIP for hair. ## Grokipedia No dedicated Grokipedia article exists for the cosmetic ingredient "sh-Polypeptide-71". A dedicated article does exist for its underlying molecule: [Vasoactive intestinal peptide](https://grokipedia.com/page/Vasoactive_intestinal_peptide) The article covers VIP's structure, its VPAC1/VPAC2 receptors, and its vasodilatory and anti-inflammatory actions, providing background on the molecule that sh-Polypeptide-71 replicates — though it does not address the topical hair-regrowth use. ## Examine No Examine.com article exists for sh-Polypeptide-71. Examine.com focuses on ingestible dietary supplements and does not cover topical cosmetic peptide ingredients. ## ConsumerLab No ConsumerLab article or product test exists for sh-Polypeptide-71. ConsumerLab evaluates ingestible supplements and does not cover topical cosmetic peptide ingredients. ## Systematic Reviews No systematic reviews or meta-analyses for sh-Polypeptide-71 were found on PubMed as of 8 July 2026. ## Mechanism of Action The proposed mechanisms for sh-Polypeptide-71 in hair are extrapolated from the known biology of VIP; none has been demonstrated for hair regrowth in humans. * **What it is and how it signals.** sh-Polypeptide-71 is synthetic VIP, a 28-amino-acid peptide belonging to the secretin/glucagon family and closely related to PACAP (pituitary adenylate cyclase-activating polypeptide, a sister signaling peptide). It acts on two receptors, VPAC1 and VPAC2 (the two docking proteins for VIP), which are GPCRs (G protein-coupled receptors — cell-surface switches that trigger internal signaling). Binding raises cyclic AMP (cAMP, an internal messenger that turns on downstream enzymes), which in turn can influence cell survival, blood-vessel tone, and inflammation. * **Proposed hair-relevant actions.** Three overlapping rationales are put forward. First, VIP is a potent vasodilator, so it is proposed to increase blood supply to the dermal papilla (the vascular cluster at the base of each follicle that feeds hair growth) — the same broad rationale used for minoxidil. Second, VIP is anti-inflammatory and shifts immune activity toward tolerance, which is proposed to calm the low-grade inflammation seen around miniaturizing follicles in androgenetic alopecia (AGA — male- and female-pattern hair loss). Third, its cAMP-driven signaling is proposed to support the activity of follicle keratinocytes and dermal papilla cells. * **Competing mechanistic view.** The assumption that VIP promotes growth is not settled. Follicle mapping shows the VIP receptor appearing in the growth-phase bulge and has led researchers to propose that VIP signaling may help *terminate* the active growth (anagen) phase rather than prolong it. If correct, topical VIP could in theory shorten rather than extend the growth phase — a direct mechanistic conflict with the marketed benefit. * **Pharmacological properties.** As a peptide, native VIP has a very short half-life in the bloodstream — on the order of one to two minutes — because it is rapidly broken down by peptidases, including DPP-4 (dipeptidyl peptidase-4, a peptide-degrading enzyme). It is not metabolized by the CYP450 system (cytochrome P450 — the liver's main drug-metabolizing enzymes), so classic drug–drug metabolic interactions are not expected. Selectivity is shared between VPAC1 and VPAC2 (and overlaps with PACAP). Tissue distribution and skin penetration of the intact peptide are poorly characterized; its large size and charge make crossing the outer skin barrier difficult, which is why cosmetic products rely on penetration enhancers, encapsulation, or delivery alongside procedures such as microneedling. ## Historical Context & Evolution * **Original intended use.** VIP was first isolated from the intestine in the early 1970s and named for its ability to widen blood vessels. Its original scientific interest was as a gut hormone, a nerve signaling molecule, and later a regulator of the immune system. A synthetic version, aviptadil, has been investigated as a medicine for conditions unrelated to hair, such as pulmonary blood-vessel disease and acute lung injury. * **Why it came to be considered for hair.** The move into hair care is recent and commercial rather than clinical. It grew out of the cosmetic industry's broader adoption of "biomimetic" growth-factor and neuropeptide ingredients — synthetic copies of the body's own signaling molecules — marketed for skin and scalp. Under cosmetic ingredient labeling (INCI — the International Nomenclature of Cosmetic Ingredients), synthetic VIP was designated sh-Polypeptide-65 and later renumbered sh-Polypeptide-71. It is typically sold as one component of multi-peptide scalp serums, on the reasoning that its blood-flow and anti-inflammatory effects might help thinning hair. * **Standing of the underlying research.** The laboratory findings that connect VIP to hair are genuine but sparse and old, and they point in two directions: some neuropeptides accelerate the growth phase while others suppress it, and the VIP receptor's appearance in the growth-phase follicle has been read as a possible "stop" signal. These findings are not debunked; they are simply preliminary and were never designed to test a topical hair product. The evolution here is one of marketing outpacing evidence: an ingredient entered consumer products before controlled hair studies were done, and that gap has not yet been closed on either side. ## Expected Benefits The benefits below are framed for risk-aware adults actively trying to preserve or regrow hair. A central caveat applies to all of them: the human evidence that exists is for multi-ingredient growth-factor serums and injectable formulations as a class, and much of it is generated or funded by the cosmetic and aesthetic companies that sell these products — a conflict of interest that should be weighed when reading efficacy claims. No controlled human study isolates sh-Polypeptide-71, so no benefit rises above speculative for this specific ingredient. ### High 🟩 🟩 🟩 No benefits reach this evidence level for sh-Polypeptide-71 as an isolated ingredient for hair regrowth. ### Medium 🟩 🟩 No benefits reach this evidence level for sh-Polypeptide-71 as an isolated ingredient for hair regrowth. ### Low 🟩 No benefits reach this evidence level for sh-Polypeptide-71 as an isolated ingredient for hair regrowth. ### Speculative 🟨 #### Improved Follicle Blood Supply VIP is a genuine and potent vasodilator, so a topical form is proposed to increase micro-circulation to the dermal papilla and thereby improve the delivery of oxygen and nutrients to growing hair. The mechanism is well established for VIP in general circulation, but there is no measurement of scalp blood flow after topical sh-Polypeptide-71, and it is unknown whether enough intact peptide even reaches the follicle. The basis is mechanistic analogy only. #### Reduced Follicle Inflammation VIP dampens inflammation and promotes immune tolerance, which is proposed to ease the low-grade inflammation that surrounds shrinking follicles in pattern hair loss and may contribute to it. This is biologically plausible and consistent with VIP's documented immune effects elsewhere, but it has not been tested in human scalp skin for this ingredient. The basis is mechanistic only. #### Prolonged Hair Growth Phase ⚠️ Conflicted The marketed premise is that sh-Polypeptide-71 helps follicles re-enter and stay in the active growth phase. The evidence directly conflicts: while some nerve-derived peptides accelerate the growth phase, follicle studies place the VIP receptor in the growth-phase bulge and suggest VIP may instead help *end* active growth. Because the same molecule has been proposed both to support and to terminate growth, the net effect on the human hair cycle is genuinely uncertain, and no controlled data resolve it. The basis is conflicting laboratory findings only. ## Benefit-Modifying Factors * **Genetic factors:** No pharmacogenetic variants are known to change the response to sh-Polypeptide-71 itself. However, the underlying condition it targets — pattern hair loss — is strongly influenced by androgen-receptor (AR) gene sensitivity, which sets how much a follicle miniaturizes and therefore how much room there is for any topical to help. * **Baseline biomarker levels:** Correctable contributors to shedding — low iron stores (ferritin), low vitamin D, thyroid imbalance, and zinc deficiency — can cap the visible benefit of any topical. A follicle limited by a nutrient or hormone problem is unlikely to respond well until that problem is addressed. * **Sex-based differences:** Pattern hair loss differs by sex in distribution and hormonal drivers, and women more often have diffuse thinning with treatable causes. Any benefit is likely to track these differences, though no sex-specific data exist for this ingredient. * **Pre-existing health conditions:** Scalp conditions such as seborrheic dermatitis or psoriasis, and systemic illness or rapid weight loss, independently drive hair loss and can blunt or mask any effect. Active scalp inflammation may also change how much peptide is absorbed. * **Age-related considerations:** Older follicles that have miniaturized over many years, including in adults at the upper end of the target age range, have less regenerative capacity, so any speculative benefit is likely smaller with advancing age. ## Potential Risks & Side Effects The risks below are framed for the target audience. Because sh-Polypeptide-71 is applied topically at low cosmetic concentrations with poor skin penetration, serious harm is unlikely; most concerns are local or theoretical. ### High 🟥 🟥 🟥 No risks reach this evidence level for sh-Polypeptide-71. ### Medium 🟥 🟥 No risks reach this evidence level for sh-Polypeptide-71. ### Low 🟥 #### Application-Site Skin Reactions The most likely adverse effect is local irritation of the scalp — redness, itching, stinging, or dryness — at the site of application. This is a general property of leave-on cosmetic serums and often reflects the excipients, preservatives, and penetration enhancers in the formula rather than the peptide itself. Reactions are typically mild and reversible on stopping. Evidence is class-level, drawn from the general use of topical peptide and growth-factor serums rather than from studies of this specific ingredient. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Allergic Contact Sensitization Peptide ingredients and the carriers they are formulated in can occasionally trigger true allergic contact dermatitis, a delayed immune reaction distinct from simple irritation. It would present as persistent redness, swelling, or a rash that worsens with repeated use. No sensitization data exist for sh-Polypeptide-71 specifically; the concern is inferred from topical cosmetics generally and from isolated reports for other peptide actives. #### Theoretical Stimulation of Unwanted Cell Growth A recurring theoretical concern for all topical growth signals is that promoting cell proliferation and new blood-vessel formation could, in principle, encourage the growth of pre-existing abnormal or pre-cancerous skin cells. VIP has trophic and blood-vessel-promoting activity, so the concern applies here in theory. There is no evidence that topical sh-Polypeptide-71 causes this, and skin penetration is low, but the possibility cannot be excluded and warrants caution on damaged or lesion-bearing scalp skin. #### Systemic Effects from Skin Absorption If a meaningful amount of intact peptide were absorbed, VIP's systemic actions — blood-vessel widening, flushing, or a drop in blood pressure — could theoretically occur. In practice this is very unlikely because the peptide is large, poorly absorbed through intact skin, and rapidly degraded, so any absorbed fraction would be broken down within minutes. The concern rises only with broken skin or delivery-assisting procedures such as microneedling. ## Risk-Modifying Factors * **Genetic factors:** No genetic variants are known to change the risk profile of sh-Polypeptide-71. General tendencies toward sensitive skin or atopic (allergy-prone) constitution may raise the chance of irritation or sensitization, but this is not specific to this ingredient. * **Baseline biomarker levels:** No blood marker is established to predict adverse reactions. Individuals with markers of active skin inflammation or barrier disruption may absorb more peptide and experience more local irritation. * **Sex-based differences:** No sex-specific safety differences are documented. Pregnancy and breastfeeding — discussed under interactions — are the main sex-related precautions, driven by absent safety data rather than known harm. * **Pre-existing health conditions:** An inflamed, broken, or diseased scalp (eczema, psoriasis, open lesions) increases absorption and irritation risk. A personal history of scalp skin cancer or pre-cancerous scalp lesions is relevant to the theoretical proliferation concern. * **Age-related considerations:** Older adults, including those at the upper end of the target range, tend to have thinner, drier, more reactive skin and a higher baseline prevalence of scalp sun damage, which may modestly raise both irritation and the theoretical proliferation concern. ## Key Interactions & Contraindications * **Prescription topical vasodilators (minoxidil):** Caution — potentially additive. Minoxidil (a blood-pressure drug repurposed as a topical hair treatment) shares the blood-flow rationale, and combining the two could increase local vasodilation and scalp irritation. Separating application timing and monitoring for excess redness or scalp discomfort limits this. * **Prescription hair drugs (finasteride, dutasteride — 5-alpha-reductase inhibitors):** No known negative interaction and plausibly complementary, since they act on hormones while this peptide is proposed to act on blood flow and inflammation. No mitigation needed beyond routine monitoring. * **Systemic vasodilators and blood-pressure drugs (sildenafil, nitrates, amlodipine):** Caution in theory only. Meaningful systemic absorption of the peptide is unlikely, but if it occurred, additive vasodilation could contribute to flushing or low blood pressure. Monitoring is warranted where the serum is applied to broken skin or over large areas. * **Over-the-counter topical retinoids and exfoliants (adapalene, glycolic acid):** Caution — these increase skin permeability and can raise both peptide absorption and irritation. Separating them in the routine or alternating days, with attention to stinging or redness, reduces this. * **Over-the-counter topical corticosteroids (hydrocortisone):** Monitor — anti-inflammatory creams may blunt or overlap with the peptide's proposed anti-inflammatory action; clinical consequence is minor. * **Supplement and cosmetic peptide combinations (GHK-Cu copper peptides, other sh-polypeptides):** Caution for cumulative irritation. These are frequently blended in the same serum; the main consequence of stacking is additive scalp irritation rather than a systemic interaction. * **Additive-effect topicals (minoxidil, niacinamide):** Included because they act on the same blood-flow and anti-inflammatory pathways the peptide targets; using several together increases the chance of local irritation without proven added benefit. * **Procedural interactions (microneedling, derma-roller, platelet-rich plasma [PRP], low-level laser therapy):** Caution — microneedling and PRP dramatically increase how much peptide and growth-factor signaling reaches the dermis, amplifying both any effect and the theoretical over-stimulation and irritation risks. Low-level laser therapy is complementary with no known negative interaction. * **Populations who should avoid it:** Absolute avoidance with known hypersensitivity to the peptide or serum excipients, and on broken, inflamed, or lesion-bearing scalp skin. Caution and avoidance is advised in pregnancy and breastfeeding (insufficient safety data), and in anyone with a history of scalp skin cancer or pre-malignant scalp lesions (theoretical growth-signal concern). These are precautionary, driven by absent data rather than demonstrated harm. ## Risk Mitigation Strategies * **Patch testing before full use:** applying a small amount to a discreet area of scalp or inner forearm for several days before regular use can reveal irritation or allergy early, mitigating application-site reactions and contact sensitization. * **Application to intact skin only:** keeping the serum off cuts, active dermatitis, sunburn, or freshly microneedled scalp for at least 24 hours limits both excess absorption (systemic effects) and irritation of compromised skin. * **Introducing one active at a time:** using the serum alone before stacking it with minoxidil, retinoids, or exfoliants allows any reaction to be traced to a single product; this mitigates cumulative irritation and sensitization. * **Separating timing from permeability-raising products:** keeping retinoids and acids in a different part of the routine (e.g., serum in the morning, retinoid at night) reduces absorption spikes and irritation. * **Limiting frequency after procedures:** pausing the serum for 24–48 hours after microneedling or PRP avoids amplified delivery, over-stimulation, and irritation of freshly injured skin. * **Avoidance in defined higher-risk situations:** foregoing use during pregnancy or breastfeeding, or over areas of prior scalp skin cancer or pre-cancerous lesions, mitigates the theoretical proliferation and unknown-safety concerns. ## Therapeutic Protocol There is no validated clinical protocol for sh-Polypeptide-71; the pattern below reflects how leading cosmetic formulators and hair-focused clinics position multi-peptide scalp serums, alongside conventional and integrative alternatives. * **Standard cosmetic use:** a few drops of the serum are applied to a clean, dry scalp over thinning areas once or twice daily and massaged in gently. It is a leave-on product and is not rinsed off. * **Competing approaches.** Conventional hair-loss care leads with proven drugs (minoxidil, finasteride) and does not include this peptide; integrative and aesthetic practitioners position peptide serums as add-ons to minoxidil, microneedling, or platelet-rich plasma. Neither approach is established as superior for this ingredient, and the peptide-serum route rests on far weaker evidence than the drug route. * **Popularizing sources:** The multi-peptide "growth-factor serum" approach has been popularized largely by cosmetic brands and aesthetic clinics rather than by a single named investigator; no independent expert or clinic has established a signature sh-Polypeptide-71 protocol. * **Best time of day:** Timing is not evidence-based; morning and/or evening application to a dry scalp is typical. If combined with minoxidil, spacing the two by a couple of hours is commonly advised to limit irritation. * **Expected half-life:** Native VIP is cleared from the bloodstream within one to two minutes, so any effect depends on how long the formulation keeps the peptide in contact with the skin rather than on lasting circulating levels; this is a core limitation of the approach. * **Single vs. split dosing:** Because retention is short, products are generally applied once or twice daily rather than as a single dose, on the assumption that repeated contact matters more than a single application. * **Genetic considerations:** No pharmacogenetic variant is known to guide dosing of this peptide. Variants that drive pattern hair loss (androgen-receptor sensitivity) affect the condition, not the peptide's handling. * **Sex-based differences:** No sex-specific dosing is established; women with diffuse thinning should first have treatable causes excluded, which influences whether a cosmetic serum is a reasonable choice at all. * **Age-related considerations:** Older follicles respond less to any stimulus; expectations should be lower for adults at the upper end of the target range, though the application method is unchanged. * **Baseline biomarker considerations:** Correcting low ferritin, low vitamin D, thyroid imbalance, or low zinc before or alongside use gives any topical its best chance and avoids attributing a nutrient-limited non-response to the product. * **Pre-existing condition considerations:** Active scalp disease should be treated first, both to improve response and to reduce absorption-related irritation. ## Discontinuation & Cycling * **Lifelong vs. short-term:** As a cosmetic aimed at an ongoing condition, any effect would require continued use; there is no defined course length and no evidence that a fixed treatment period produces lasting change. * **Withdrawal effects:** No withdrawal syndrome is known. As with other hair actives, whatever cosmetic benefit accrues is expected to fade gradually after stopping as follicles return to their untreated trajectory. * **Tapering:** No taper is needed; the product can simply be stopped, since it produces no dependence and no rebound is documented. * **Cycling:** Cycling has not been studied and is not established as beneficial; there is no mechanistic reason that on-off cycling would maintain efficacy for a topical peptide. * **Practical framing:** Because benefit is unproven, discontinuation is low-stakes — the main consequence is loss of any cosmetic gain and the cost saved, not a health risk. ## Sourcing and Quality * **Ingredient identity:** the exact INCI name "sh-Polypeptide-71" appears on the ingredient list; it is almost always one of several peptides in a blend rather than a standalone product, so its position on the list (and thus its concentration) is usually low and undisclosed. * **Formulation and stability:** peptides degrade with heat, light, and time, so products in opaque, air-restricting packaging (pumps or sealed droppers) with clear storage instructions are preferable; a serum that does not protect its peptides may deliver little intact ingredient. * **Purity and manufacturing:** Because these are recombinant or synthetic peptides, purity and correct sequence depend on the manufacturer; reputable cosmetic brands that disclose their peptide suppliers and support claims with any testing are preferable to anonymous white-label products. * **Third-party testing:** Independent verification is uncommon in cosmetics, and there is no established purity certification for this ingredient; in the absence of published data, concentration and "clinically proven" claims warrant skepticism. * **Reputable sourcing:** No specific brand has independently validated sh-Polypeptide-71 for hair; established cosmetic manufacturers with transparent formulations are preferable to sellers making strong regrowth claims, and compounded or unbranded peptide serums of unknown origin warrant caution. ## Practical Considerations * **Time to effect:** Hair responds slowly; any cosmetic change would take at least 3–6 months of consistent daily use to become visible, matching the hair cycle, and results may never reach the level of proven drugs. * **Common pitfalls:** The most common mistakes are expecting drug-level regrowth from a cosmetic, stopping before 3–6 months, using it instead of (rather than alongside) proven options, and not first ruling out treatable causes of shedding. * **Regulatory status:** sh-Polypeptide-71 is sold as a cosmetic ingredient, not an approved drug; it has not been reviewed by the FDA (U.S. Food and Drug Administration) for hair regrowth, and products may make only limited cosmetic claims. Cosmetic ingredient safety is assessed through bodies such as the CIR (Cosmetic Ingredient Review), not through drug-efficacy trials. * **Cost and accessibility:** Multi-peptide "growth-factor" serums are typically premium-priced and not covered by insurance; the cost can be substantial over the many months needed to judge any effect, which is a meaningful consideration given the unproven benefit. * **Setting expectations:** It is best viewed as an experimental cosmetic add-on with a plausible but unproven rationale, not a replacement for evidence-based hair-loss treatment. ## Interaction with Foundational Habits * **Sleep:** Indirect interaction. VIP is one of the signals in the brain's master clock, and disrupted sleep worsens the stress and inflammation that drive shedding; there is no evidence a topical serum affects sleep, but good sleep supports the follicle environment the product is meant to help. * **Nutrition:** Indirect, potentiating. Adequate protein, iron, zinc, and vitamin D are prerequisites for hair growth; a nutrient-limited follicle will not respond to any topical, so correcting deficiencies is likely to determine whether the serum can do anything at all. No specific foods interact with the peptide directly. * **Exercise:** Indirect, potentiating. Regular exercise improves overall circulation and lowers systemic inflammation, complementing the blood-flow and anti-inflammatory rationale of the ingredient; there is no need to time application around workouts, though applying to a sweat-free, clean scalp aids absorption. * **Stress management:** Indirect. Psychological stress can trigger diffuse shedding (telogen effluvium) and promote scalp inflammation; since the peptide is proposed to act partly by calming inflammation, reducing stress works in the same direction. Affecting cortisol is not an established action of the topical itself. ## Monitoring Protocol & Defining Success Because sh-Polypeptide-71 is a cosmetic with unproven benefit, monitoring centers on excluding treatable causes of hair loss before starting and on tracking visible change over time. Baseline laboratory testing is used not to dose the peptide but to find and correct contributors to shedding that would otherwise limit any result. Ongoing review is mainly visual, with standardized photographs at baseline, then at 3 months and 6 months, and every 6 months thereafter, since hair change is slow. * **Baseline testing:** Before starting, standardized scalp/hairline photographs under consistent lighting are taken, and the blood markers below are checked to rule out reversible drivers of hair loss. * **Ongoing monitoring cadence:** standardized photographs are repeated at 3 months, 6 months, and then every 6 months; any abnormal baseline blood marker is rechecked after it has been treated, typically at 3 months. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Ferritin | 40–70 ng/mL (women); 50–150 ng/mL (men) | Low iron stores are a common, reversible cause of shedding | Conventional "normal" can start near 15–30 ng/mL, well below the functional target; ferritin also rises with inflammation, so it is best paired with CRP (C-reactive protein, a general inflammation marker) if unclear | | Vitamin D (25-hydroxyvitamin D) | 40–60 ng/mL | Low vitamin D is linked to hair thinning and poor follicle cycling | Conventional sufficiency is often set at ≥30 ng/mL; no fasting required | | TSH | 1.0–2.0 mIU/L | Thyroid imbalance is a reversible cause of diffuse hair loss | TSH = thyroid-stimulating hormone; conventional range extends to ~4.5 mIU/L; best drawn in the morning | | Serum zinc | 90–120 µg/dL | Zinc deficiency can trigger telogen shedding | Best drawn fasting in the morning; interpreted alongside copper, which zinc can deplete | | DHEA-S and free testosterone | Lab- and sex-specific reference | Screens for hormone-driven pattern loss, especially in women | DHEA-S = dehydroepiandrosterone sulfate; best drawn in the morning, and in the early cycle for menstruating women | * **Qualitative markers of success:** * **Reduced shedding:** Fewer hairs lost during washing and brushing, judged consistently over weeks. * **Visible density and coverage:** Improvement in standardized photographs at the part line and temples rather than day-to-day impressions. * **Hair quality:** Subjective sense of thicker, stronger, or faster-growing hair. * **Scalp comfort:** Absence of irritation, redness, or itching, which also signals good tolerability. ## Emerging Research * **No trials of the specific ingredient:** A search of clinicaltrials.gov returned no registered clinical trials evaluating sh-Polypeptide-71 (synthetic VIP) for hair regrowth as of 8 July 2026. This absence is itself the central research gap: the ingredient is marketed ahead of any registered human hair study. * **Category-level human evidence (could strengthen the case):** The closest supporting evidence is for injectable growth-factor and biomimetic-polypeptide formulations in pattern hair loss, summarized in a systematic review — [Effectiveness of minimally invasive injectable modalities in the management of androgenetic alopecia among adults — A systematic review](https://pubmed.ncbi.nlm.nih.gov/39176982/) (Kumar et al., 2024) — which reports satisfactory but low-quality evidence for growth-factor formulations. It does not test sh-Polypeptide-71, so it supports the category, not the ingredient. * **Mechanistic work that could weaken the case:** Follicle mapping placing the VIP receptor in the growth-phase bulge and proposing a growth-terminating role — [Wollina et al., 1995](https://pubmed.ncbi.nlm.nih.gov/7756742/) — points to a direction in which VIP could fail to help or even hinder regrowth. Confirming whether topical VIP extends or shortens the human growth phase is the single most decisive open question. * **Delivery science:** Because intact VIP penetrates skin poorly and degrades within minutes, future work on encapsulation, stabilized analogs, and procedure-assisted delivery (microneedling) will determine whether enough active peptide can reach the follicle for any effect to be possible; this is a prerequisite for meaningful efficacy trials. * **Future direction — controlled topical trials:** The field needs randomized, placebo-controlled studies of the isolated ingredient with objective hair-count and density endpoints, since current claims rest on mechanism and multi-ingredient products rather than on evidence for sh-Polypeptide-71 itself. ## Conclusion sh-Polypeptide-71 is a synthetic copy of vasoactive intestinal peptide, a natural body signal that widens blood vessels and calms inflammation, now sold as a leave-on ingredient in scalp serums for thinning hair. Its case for hair regrowth rests entirely on plausibility: if better blood flow and less inflammation help elsewhere, perhaps they help the follicle. That reasoning is reasonable but untested. No controlled human study has examined this ingredient for hair, and the limited laboratory work is mixed — some of it hints that this signal may help end, rather than extend, the hair's active growth phase. Much of the supporting material comes from the companies that sell these serums, which is a reason for added caution when reading their claims. The likely downsides are modest, mainly scalp irritation, with only theoretical concerns beyond that because so little of the peptide penetrates the skin. Set against proven options, it should be seen as an experimental, premium-priced add-on with an unproven benefit rather than a treatment one can count on. For now, the gap between a plausible rationale and the absence of any direct human evidence is what most defines its place among hair interventions. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**